C
CytomX Therapeutics, Inc. (CTMX)
NMS – Real vaqt narxi. Valyuta: USD
3.88
+0.02 (0.52%)
Yopilishda: May 12, 2026, 4:00 PM EDT
3.92
+0.04 (0.98%)
Bozor oldidan: May 13, 2026, 4:00 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
3.88
+0.02 (0.52%)
Yopilishda: May 12, 2026, 4:00 PM EDT
3.92
+0.04 (0.98%)
Bozor oldidan: May 13, 2026, 4:00 AM EDT
CytomX Therapeutics, Inc. onko-onkologiyaga yo'naltirilgan biofarmatsevtika kompaniyasi bo'lib, u o'simta mikro-muhitini davolash uchun mo'ljallangan kuchli biologik vositalarni ishlab chiqishga qaratilgan. Kompaniya onkologik biologik vositalarni tadqiq qilish va ishlab chiqish uchun shartli aktivatsiya platformasi texnologiyasidan foydalanadi, bu esa antitel-dorilar kon'yugatlarining (ADC) maqsadlarini tasdiqlash, qattiq o'smalarga qarshi yangi T-hujayra konstruktorlari (TCE) uchun terapevtik oynani ochish va sitokinlar kabi immunitetni modulyatsiya qiluvchilar uchun terapevtik indeksni oshirishni o'z ichiga oladi; shuningdek, onkologiya sohasidan tashqarida preklinik tadqiqotlarda PROBODY platformasi. Shuningdek, u o'simta hujayralaridagi epidermis o'sish omili retseptoriga (EGFR) va T-hujayralardagi CD3 retseptoriga qarshi yo'naltirilgan T-hujayra konstruktorli bispesifik antitel bo'lgan CX-904; kolorektal rak kabi EpCAM-ifodalovchi epiteliya raklari uchun terapevtik indeksni optimallashtirish uchun shartli ravishda faollashtirilgan ADC bo'lgan CX-2051; va interferon alfa-2b PROBODY sitokin bo'lgan CX-801ni ishlab chiqadi. Bundan tashqari, kompaniyaning ishlab chiqish liniyasi CD71 ga qarshi yo'naltirilgan shartli ravishda faollashtirilgan ADC bo'lgan CX-2029; va ne-fukozillangan ipilimumabning PROBODY versiyasi bo'lgan BMS-986288 ni o'z ichiga oladi. Kompaniya Amgen, Astellas, Bristol Myers Squibb, Regeneron va Moderna bilan strategik hamkorlikka ega; va Merck bilan CX-801ni anti-PD-1 terapiyasi, KEYTRUDA (pembrolizumab) bilan birgalikda baholash uchun klinik sinov hamkorligi va ta'minot shartnomasiga ega. Kompaniya 2008-yilda tashkil etilgan va Janubiy San-Fransisko, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Marcia P. Belvin Ph.D. | Senior VP & Chief Scientific Officer |
| Dr. Sean A. McCarthy DPHIL | Chairman & CEO |
| Dr. Stephanie Robertson Ph.D. | Senior Vice President of Alliances & Program Leadership |
| Dr. Yu-Waye Chu M.D. | Senior VP & Chief Medical Officer |
| Mr. Christopher W. Ogden | SVP, CFO & Secretary |
| Mr. Lloyd A. Rowland Jr., J.D. | Senior VP, General Counsel, Chief Compliance Officer & Secretary |
| Ms. Danielle Olander-Moghadassian | Senior VP & Chief Human Resources Officer |
| Ms. Dawn Benson | Senior Vice President of Quality & Product Manufacturing |
| Ms. Leslie Robbins J.D. | Senior Vice President of Intellectual Property |
| Ms. Rachael Lester | Chief Business Officer & Senior VP |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-07 | 10-Q | ctmx-20260331.htm |
| 2026-04-30 | DEF 14A | ny20064651x2_def14a.htm |
| 2026-04-20 | PRE 14A | ny20064651x1_pre14a.htm |
| 2026-03-19 | 8-K | d100765d8k.htm |
| 2026-03-16 | 10-K | ctmx-20251231.htm |
| 2025-11-06 | 8-K | ctmx-20251106.htm |
| 2025-08-14 | CORRESP | filename1.htm |
| 2025-08-13 | 8-K | d925542d8k.htm |
| 2025-08-07 | S-8 | d119770ds8.htm |
| 2025-08-07 | S-3 | d127103ds3.htm |